诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVS 诺华

已收盘 06-05 16:00:00 EDT

99.37

+0.46

+0.47%

盘后99.80

+0.43+0.43%

17:43 EDT

最高99.99	最低99.18	成交量263.58万
今开99.85	昨收98.91	日振幅0.82%
总市值2,084亿	流通市值1,993亿	总股本20.97亿
成交额2.63亿	换手率0.13%	流通股本20.06亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVS","market":"US","secType":"STK","nameCN":"诺华","latestPrice":99.37,"timestamp":1685995200000,"preClose":98.91,"halted":0,"volume":2635785,"hourTrading":{"tag":"盘后","latestPrice":99.8,"preClose":99.37,"latestTime":"17:43 EDT","volume":10677,"amount":1061065.6715,"timestamp":1686001410290},"delay":0,"floatShares":2005911622,"shares":2097395834,"eps":3.247357,"marketStatus":"已收盘","marketStatusCode":5,"change":0.46,"latestTime":"06-05 16:00:00 EDT","open":99.85,"high":99.99,"low":99.1801,"amount":262631884.1751,"amplitude":0.008188,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.247357,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1686038400000},"adr":1,"adjPreClose":98.91,"adrRate":1,"dividendRate":0.034826,"preHourTrading":{"tag":"盘前","latestPrice":99.86,"preClose":98.91,"latestTime":"09:28 EDT","volume":4154,"amount":413947.80314,"timestamp":1685971710107},"postHourTrading":{"tag":"盘后","latestPrice":99.8,"preClose":99.37,"latestTime":"17:43 EDT","volume":10677,"amount":1061065.6715,"timestamp":1686001410290},"volumeRatio":0.900147,"optionData":{"bulkOrders":[{"symbol":"NVS","call":false,"expireDate":1686888000000,"strike":"95.0","timestamp":1685979623183,"price":0.10000000149011612,"volume":3700,"amount":37000,"type":"-"}]}},"requestUrl":"/m/hq/s/NVS","defaultTab":"news","newsList":[{"id":"2339849009","title":"印度成功发射导航卫星GSLV-F12和NVS-01","url":"https://stock-news.laohu8.com/highlight/detail?id=2339849009","media":"环球网","top":-1,"share":"https://www.laohu8.com/m/news/2339849009?lang=zh_CN&edition=full","pubTime":"2023-05-29 14:11","pubTimestamp":1685340660,"startTime":"0","endTime":"0","summary":"据印度媒体报道，当地时间29日上午，印度空间研究组织成功发射导航卫星GSLV-F12和NVS-01。（总台记者 宋焕钰）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2023-05-29/doc-imyvmrnz5245409.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2023-05-29/doc-imyvmrnz5245409.shtml","is_publish_highlight":false},{"id":"2337775179","title":"诺华制药跌0.25% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2337775179","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2337775179?lang=zh_CN&edition=full","pubTime":"2023-05-24 21:32","pubTimestamp":1684935177,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023052421325782cbac2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023052421325782cbac2f&s=b","is_publish_highlight":false},{"id":"2336535944","title":"诺华制药跌1.21% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2336535944","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2336535944?lang=zh_CN&edition=full","pubTime":"2023-05-18 23:40","pubTimestamp":1684424458,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305182340588471c03f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305182340588471c03f&s=b","is_publish_highlight":false},{"id":"2335185859","title":"诺华制药(NVS.US)在分拆前任命山德士董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2335185859","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2335185859?lang=zh_CN&edition=full","pubTime":"2023-05-15 15:41","pubTimestamp":1684136479,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/930315.html","is_publish_highlight":false},{"id":"2333459325","title":"AZ坐稳龙头，百济、诺华、BMS并列第7！2023全球制药创新和发明指数TOP30都有谁？","url":"https://stock-news.laohu8.com/highlight/detail?id=2333459325","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2333459325?lang=zh_CN&edition=full","pubTime":"2023-05-06 11:00","pubTimestamp":1683342000,"startTime":"0","endTime":"0","summary":"　　5月4日，IDEA Pharma发布了全球制药创新和发明指数，辉瑞和AZ分别位列两个榜单的首位；创新指数今年变化颇大，以前十为例，BMS、BI、礼来等6家都是新进前十。作为中国唯一的代表，百济神州分别录得第18名、第7名，不过其在创新指数中下滑了12名，在发明指数中则守住了自己的位置。　　5月4日，IDEA Pharma发布了全球的“2023制药创新和发明指数”，来评估全球TOP30制药公司的创新性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/med/zbsc/2023-05-06/doc-imysvfmy3064272.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/med/zbsc/2023-05-06/doc-imysvfmy3064272.shtml","is_publish_highlight":false},{"id":"2332015532","title":"诺华制药(NVS.US)旗下山德士将在美国独家商业化六种产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2332015532","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2332015532?lang=zh_CN&edition=full","pubTime":"2023-05-04 16:29","pubTimestamp":1683188944,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药(NVS.US)旗下仿制药公司山德士周四宣布，该公司已与Adalvo签署了一项分销和合作协议，山德士获得六种产品在美国的独家商业化权利。这些产品涵盖关键的治疗领域，包括抗真菌/抗生素，肿瘤和肺部。预计这六种产品中有四种将率先上市。这些产品计划于2024年开始推出，潜在市场总规模约为30亿美元。此次合作预计将进一步推进山德士在美国主要仿制药市场的产品线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/925782.html","is_publish_highlight":false},{"id":"2330138994","title":"隔夜美股全复盘(4.26)| 三大股指均跌逾1%，连串负面消息拖累美股下跌；微软业绩超预期，盘后一度涨逾9%，云业务营收维持两位数增长；谷歌顶住微软AI冲击，一季度搜索重回增长，云业务扭亏为盈，盘后一度涨超4%，将回购最多700亿美元的A类和C类股","url":"https://stock-news.laohu8.com/highlight/detail?id=2330138994","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2330138994?lang=zh_CN&edition=full","pubTime":"2023-04-26 08:27","pubTimestamp":1682468821,"startTime":"0","endTime":"0","summary":"三大股指均跌逾1%，连串负面消息拖累美股下跌；微软业绩超预期，盘后一度涨逾9%，云业务营收维持两位数增长；谷歌顶住微软AI冲击，一季度搜索重回增长，云业务扭亏为盈，盘后一度涨超4%，将回购最多700亿美元的A类和C类股","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/597730","is_publish_highlight":false},{"id":"2330050841","title":"【美股盘前异动】诺华制药涨超2%，Q1收入、利润均超过市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2330050841","media":"英为财情","top":-1,"share":"https://www.laohu8.com/m/news/2330050841?lang=zh_CN&edition=full","pubTime":"2023-04-25 16:25","pubTimestamp":1682411125,"startTime":"0","endTime":"0","summary":"英为财情Investing.com - 周二美股盘前，诺华制药 升逾2%，报103.06美元。诺华制药公布的2023年第一季度业绩报告显示，公司Q1收入129.5亿美元，好于市场预期，Q1盈利22.94亿美元，也好于市场预期。此外，诺华制药上调2023年全年营收预期和核心经营利润预期，预计营收将增长4-6%，此前为1-5%；预计核心经营利润将增长7-9%，此前为4-6%。资金狂抄底医疗ETF. 华尔街传奇投资人比尔·艾克曼的投资组合一览：安全第一！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://cn.investing.com/news/stock-market-news/article-2197073","is_publish_highlight":false},{"id":"2330810153","title":"诺华制药(NVS.US)Q1销售额同比增长3% 上调全年盈利预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2330810153","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2330810153?lang=zh_CN&edition=full","pubTime":"2023-04-25 14:46","pubTimestamp":1682405180,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药上调了全年盈利预期，称其增长势头强劲，原因是一种关键的乳腺癌药物试验取得成功，并在促进前列腺癌放疗药物生产方面取得进展。诺华制药第一季度销售额同比增长3%，至129.5亿美元，高于分析师预期的125.5亿美元，这主要得益于银屑病关节炎药物Cosentyx的销售额好于预期。每股收益为1.71美元，好于市场预期，上年同期为1.46美元。诺华一直在努力提高治疗前列腺癌的Pluvicto的产量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/917546.html","is_publish_highlight":false},{"id":"2324982358","title":"华海药业副总裁尚飞离职：年薪180万，在10位副总排第4，曾就职于辉瑞、赛诺菲、诺华制药、玛氏、中美史克等","url":"https://stock-news.laohu8.com/highlight/detail?id=2324982358","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2324982358?lang=zh_CN&edition=full","pubTime":"2023-04-04 11:52","pubTimestamp":1680580320,"startTime":"0","endTime":"0","summary":"浙江华海药业股份有限公司近日发布公告，宣布公司副总裁尚飞女士已递交离职申请，并已被公司董事会批准。据悉，尚飞女士的离职文件自送达公司董事会之日起生效，她将不再担任公司任何职务。　　公司表示，尚飞女士在任职期间为公司的发展做出了重要的贡献，对此表示感谢。　　2021年报显示，当年华海药业共有10位副总裁，其中，尚飞女士年薪180万元，薪酬在公司高管中处于中等水平。2019年5月至2023年3月任华海药业副总裁。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/med/zbsc/2023-04-04/doc-imyperrh5020201.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/med/zbsc/2023-04-04/doc-imyperrh5020201.shtml","is_publish_highlight":false},{"id":"2322286957","title":"德银：诺华制药(NVS.US)乳腺癌药物Kisqali试验结果积极 上调评级至“持有”","url":"https://stock-news.laohu8.com/highlight/detail?id=2322286957","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2322286957?lang=zh_CN&edition=full","pubTime":"2023-03-28 10:41","pubTimestamp":1679971269,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德意志银行分析师Emmanuel Papadakis发布研报称，将对诺华制药(NVS.US)的评级由 “卖出”上调至“持有”，目标价80瑞郎。该分析师称，诺华制药周一早些时候发布的乳腺癌药物Kisqali(核糖ciclib)第三阶段试验的正面一线结果十分积极。Papadakis表示，虽然诺华制药预计NATALEE试验会取得积极结果，但预计最终分析结果将在2023年下半年公布。其补充称，试验重要结果是药物“对高/中风险患者有一致的好处”。诺华制药在 NATALEE 的HR+/HER2早期乳腺癌症患者中，对Kisqali进行内分泌治疗辅助治疗与单独内分泌治疗进行了对比试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/900037.html","is_publish_highlight":false},{"id":"1137758299","title":"盘前 | 硅谷银行将被“接盘”！第一公民银行股份飙涨近40%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137758299","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1137758299?lang=zh_CN&edition=full","pubTime":"2023-03-27 19:50","pubTimestamp":1679917804,"startTime":"0","endTime":"0","summary":"","market":"sh","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true},{"id":"2322446835","title":"美股异动|诺华制药盘前涨6%旗下靶向抗癌药3期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2322446835","media":"和讯","top":-1,"share":"https://www.laohu8.com/m/news/2322446835?lang=zh_CN&edition=full","pubTime":"2023-03-27 17:12","pubTimestamp":1679908355,"startTime":"0","endTime":"0","summary":"美股异动|诺华制药盘前涨6%旗下靶向抗癌药3期临床试验达到主要终点：诺华制药(NVS.US)盘前涨5.98%，报88.59美元。公司旗下靶向抗癌药物Kisqali联合治疗早期乳腺癌3期临床试验达到主要终点。根据诺华制药的说法，与单独的标准辅助内分泌治疗相比，Kisqali联合内分泌治疗显著降低了疾病复发的风险，无论有无淋巴结受累性，对2期和3期的早期乳腺癌患者均有一致的受益。资料显示，Kisqali已在全球99个国家或地区获得批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023032717162182715d6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023032717162182715d6d&s=b","is_publish_highlight":false},{"id":"2322741442","title":"诺华制药(NVS.US)旗下靶向抗癌药物Kisqali联合治疗早期乳腺癌3期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2322741442","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2322741442?lang=zh_CN&edition=full","pubTime":"2023-03-27 15:18","pubTimestamp":1679901525,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药宣布，评估旗下靶向抗癌药物Kisqali联合内分泌治疗在HR+/HER2-早期乳腺癌辅助治疗中的疗效的3期NATALEE临床试验达到了主要终点。根据诺华制药的说法，与单独的标准辅助内分泌治疗相比，Kisqali联合内分泌治疗显著降低了疾病复发的风险，无论有无淋巴结受累性，对2期和3期的早期乳腺癌患者均有一致的受益。资料显示，Kisqali已在全球99个国家或地区获得批准。欧盟同样批准了Kisqali用于一线治疗HR+/HER2-乳腺癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/899092.html","is_publish_highlight":false},{"id":"2321095362","title":"诺华(NVS.US)：不会继续推进英国抗胆固醇药物试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2321095362","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2321095362?lang=zh_CN&edition=full","pubTime":"2023-03-22 17:08","pubTimestamp":1679476121,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华周三表示，已决定不再推进ORION-17的初级预防试验。据了解，ORION-17原计划是该公司与英国国民医疗服务体系合作的一部分，目的是调查抗胆固醇药物Leqvio的潜力。此前，诺华于2021年曾表示，在英国医疗成本机构NICE批准该药物后，该公司已与英国医疗服务提供商就使用该制药商的抗胆固醇药物Leqvio达成协议。这家制药公司当时表示，该协议将帮助有心脏病风险、常规治疗无效的人通过英国国家医疗服务体系广泛获得这家瑞士制药商的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/896402.html","is_publish_highlight":false},{"id":"2319003179","title":"传诺华制药(NVS.US)着手出售部分眼科资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2319003179","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2319003179?lang=zh_CN&edition=full","pubTime":"2023-03-14 19:16","pubTimestamp":1678792578,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据知情人士透露，诺华制药正着手出售部分眼科资产，以削减投资组合并专注于增长领域。这些人士表示，诺华预计这些资产将吸引私人股本和战略竞购者的兴趣，并已开始接洽可能的竞购者。评估工作正在进行中，诺华仍可能决定保留这些资产。媒体去年报道称，诺华正在考虑出售其眼科和呼吸部门的全部或部分业务。这位发言人称，诺华仍然致力于眼科领域。截至发稿，诺华制药盘前涨0.23%，报81.80美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/891681.html","is_publish_highlight":false},{"id":"2319797032","title":"诺华制药(NVS.US)启动新一轮股票回购 价值高达109亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2319797032","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2319797032?lang=zh_CN&edition=full","pubTime":"2023-03-13 16:11","pubTimestamp":1678695070,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药(NVS.US)已启动了一轮新的股票回购，计划在未来3年内花费最高达100亿瑞士法郎(约合109亿美元)回购至多10%的股票。在上周的年度股东大会上，诺华制药的股东们批准了将用于股票回购的剩余65亿瑞士法郎的授权进行展期，使得股票回购的剩余授权的总金额达到100亿瑞士法郎。该公司刚刚完成了在2020年3月至2023年3月10日期间回购2.13亿股股票的计划，相当于该公司8.9%的股份。这些股份要么已经被注销，要么在年度股东大会上被提议注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/890786.html","is_publish_highlight":false},{"id":"2314111346","title":"百洋医药(301015.SZ)与北京诺华合作推广抗癌药维全特","url":"https://stock-news.laohu8.com/highlight/detail?id=2314111346","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2314111346?lang=zh_CN&edition=full","pubTime":"2023-02-26 16:42","pubTimestamp":1677400979,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百洋医药 发布公告，近日，百洋医药与北京诺华制药有限公司签署了《推广协议》，双方约定通过百洋医药进行的推广活动将指定产品的推广和营销扩展到指定区域内的医疗机构和零售终端。据悉，公司与北京诺华合作推广的维全特，适用于晚期肾细胞癌患者的一线治疗或曾接受细胞因子治疗的晚期肾细胞癌患者的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/882708.html","is_publish_highlight":false},{"id":"2309352363","title":"FDA即将审查诺华制药(NVS.US)旗下山德士的仿制药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2309352363","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2309352363?lang=zh_CN&edition=full","pubTime":"2023-02-06 15:20","pubTimestamp":1675668005,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞士医药巨头诺华制药(NVS.US)旗下子公司山德士(Sandoz)宣布，FDA已接受其拟推出的生物仿制药地诺单抗(denosumab)生物制剂许可证的申请(BLA)，接下来将进行审查。BLA包括分析和临床数据包，以及包括来自I/III期ROSALIA研究的相关数据。山德士公司总裁兼北美地区负责人Keren Haruvi表示:“denosumab除了是治疗骨癌的重要药物外，在治疗骨质疏松症和潜在预防骨质疏松症相关骨折方面也有着至关重要的作用，许多50岁以上的女性都有患上骨质疏松症的风险。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/871739.html","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0107},{"period":"1month","weight":-0.053},{"period":"3month","weight":0.168},{"period":"6month","weight":0.0991},{"period":"1year","weight":0.1016},{"period":"ytd","weight":0.0903}],"websiteUrl":"http://www.novartis.com","compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0488},{"period":"3month","weight":0.0587},{"period":"6month","weight":0.0516},{"period":"1year","weight":0.0252},{"period":"ytd","weight":0.1189}],"name":"诺华","description":"Novartis AG于1996年2月29日在瑞士成立。该公司提供满足全球患者和社会不断变化的需求的医疗保健解决方案。 他们广泛的产品组合包括创新药物和肿瘤药物，仿制药和生物仿制药以及眼科护理设备。 他们的使命是发现改善和延伸人们生活的新方法。 他们的愿景是成为改变医学实践的值得信赖的领导者。 他们的战略是利用科学的创新在不断增长的医疗领域提供更好的患者结果。","yearOnYearQuotes":[{"month":1,"riseRate":0.347826,"avgChangeRate":-0.016709},{"month":2,"riseRate":0.434783,"avgChangeRate":-0.011667},{"month":3,"riseRate":0.521739,"avgChangeRate":0.002426},{"month":4,"riseRate":0.695652,"avgChangeRate":0.019381},{"month":5,"riseRate":0.652174,"avgChangeRate":0.006502},{"month":6,"riseRate":0.541667,"avgChangeRate":0.008897},{"month":7,"riseRate":0.695652,"avgChangeRate":0.011738},{"month":8,"riseRate":0.391304,"avgChangeRate":-0.005433},{"month":9,"riseRate":0.695652,"avgChangeRate":0.011868},{"month":10,"riseRate":0.478261,"avgChangeRate":-0.00729},{"month":11,"riseRate":0.608696,"avgChangeRate":0.015278},{"month":12,"riseRate":0.695652,"avgChangeRate":0.02295}],"exchange":"NYSE","nameEN":"Novartis AG","compareStock":{"symbol":"SPY","name":"标普500ETF"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.13.0","shortVersion":"4.13.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺华,NVS,诺华股票,诺华股票老虎,诺华股票老虎国际,诺华行情,诺华股票行情,诺华股价,诺华股市,诺华股票价格,诺华股票交易,诺华股票购买,诺华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}